YAP-TEAD Pathway Drives PPARα-Induced Liver Regeneration in Mice

Study Background and Research Question

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor central to the regulation of lipid metabolism, inflammation, and energy homeostasis in the liver. Pharmacological activation of PPARα, most notably by selective agonists such as WY-14643 (Pirinixic Acid), has been widely studied for its effects on metabolic disorders and hepatic physiology. However, the precise downstream mechanisms connecting PPARα activation to liver growth and regeneration have remained incompletely defined. The reference study, "YAP-TEAD mediates peroxisome proliferator-activated receptor α induced hepatomegaly and liver regeneration in mice", addresses a key question: What are the molecular mediators of PPARα-induced hepatomegaly and what role does the YAP-TEAD pathway play in this process?

Key Innovation from the Reference Study

The principal innovation lies in the elucidation of the YAP-TEAD transcriptional module as a required mediator of PPARα-driven hepatomegaly and liver regeneration. While earlier studies have established the metabolic and anti-inflammatory effects of PPARα agonists, this work uncovers the necessity of the YAP (Yes-associated protein) and TEAD (TEA domain family) signaling axis for translating metabolic cues into proliferative and regenerative responses within hepatic tissue. This provides a mechanistic bridge between metabolic regulation and tissue growth, broadening the known functional landscape of PPARα activation in vivo.

Methods and Experimental Design Insights

The study employed a rigorous in vivo experimental design using multiple genetically engineered mouse models to dissect the roles of PPARα and YAP in liver physiology:

• Wild-type C57BL/6 mice were used to establish baseline responses to PPARα activation.
• Liver-specific PPARα knockout (PparaΔHep) mice enabled the assessment of hepatocyte-autonomous PPARα function.
• Liver-specific YAP knockout (YapΔHep) mice and AAV-mediated YAP knockdown models allowed for targeted interruption of the YAP-TEAD pathway.

For pharmacological interventions, WY-14643 (100 mg/kg/day, intraperitoneally) was administered for 10 days, with corn oil serving as vehicle control. Partial hepatectomy (PHx) models were employed to probe regenerative responses. Additionally, verteporfin was used to disrupt YAP-TEAD interactions. Liver and serum samples were collected at multiple time points for histological (H&E, Ki67, β-catenin) and biochemical analyses (ALT, AST, ALP, ALB, TBA, TBIL). Quantitative real-time PCR (qPCR) assessed gene expression profiles.

Protocol Parameters

• WY-14643 administration: 100 mg/kg/day intraperitoneally for 10 days in mice, as implemented to activate PPARα-dependent pathways.
• Partial hepatectomy (PHx): Performed to induce liver regeneration; tissue harvested 2 and 5 days post-surgery.
• YAP-TEAD inhibition: Verteporfin at 100 mg/kg/day intraperitoneally for 5 days to block the interaction and assess the necessity of this pathway.
• YAP knockdown: AAV-shRNA (1.1 × 10¹¹ genome copies per mouse) delivered intravenously, followed by a 4-week wait before WY-14643 challenge.
• Sample handling: Livers snap-frozen in liquid nitrogen or fixed in 10% formalin for histology.

Core Findings and Why They Matter

The study provides compelling evidence that PPARα activation by WY-14643 robustly induces hepatomegaly and stimulates liver regeneration following PHx in wild-type mice. These effects were absent in PPARα-deficient models, confirming receptor specificity. Crucially, disruption of YAP function—either by genetic knockout, AAV-mediated knockdown, or pharmacological TEAD inhibition—abolished these proliferative responses, demonstrating that YAP-TEAD is indispensable for translating PPARα signaling into hepatic growth. Histologically, this was reflected in increased hepatocyte size and proliferation (Ki67+ cells), and biochemically in improved markers of liver function.

This mechanistic insight links metabolic signaling (via PPARα) to regenerative growth (via YAP-TEAD), with implications extending to liver disease, metabolic disorder research, and therapeutic strategies leveraging insulin sensitivity enhancement and anti-inflammatory modulation in endothelial cells. The study underscores the specificity and utility of using a selective PPARα agonist for metabolic research workflows focused on tissue regeneration.

Comparison with Existing Internal Articles

Several internal resources offer complementary perspectives on WY-14643 (Pirinixic Acid). For example, "WY-14643 (Pirinixic Acid): Unlocking PPARα Signaling for..." provides a comprehensive overview of PPARα-driven metabolic and inflammatory pathways, including its role in liver regeneration. This aligns with the reference study's demonstration of WY-14643's capacity to modulate both metabolic and proliferative processes. Similarly, "WY-14643: Selective PPARα Agonist for Metabolic Research..." details the compound's dual agonist activity and practical protocol optimization, reinforcing the methodological rigor and translational relevance of the reference study's approach.

These resources collectively highlight the reproducibility and workflow compatibility of WY-14643 in metabolic disorder research, supporting its use in experiments targeting lipid metabolism regulation and insulin sensitivity. However, the reference paper advances mechanistic understanding by directly implicating the YAP-TEAD pathway, a nuance not fully addressed in prior workflow-focused reviews.

Limitations and Transferability

Despite its mechanistic depth, the study is constrained by its reliance on murine models, which may not fully recapitulate human liver physiology or disease states. The use of high-dose WY-14643 and genetic knockouts provides clear experimental contrasts but raises questions about dose translation and off-target effects in other species or contexts. Additionally, while the YAP-TEAD axis is demonstrated as necessary for PPARα-induced hepatomegaly, the broader implications for chronic liver disease or cancer remain to be explored. Researchers should be cautious in extrapolating these findings to clinical scenarios without further validation.

Research Support Resources

For investigators aiming to model PPARα-driven metabolic regulation or to study liver regeneration mechanisms, WY-14643 (Pirinixic Acid) (SKU A4305) is available as a solid, highly selective agonist suitable for in vivo and in vitro protocols. Detailed product information, including storage, solubility, and workflow optimization, can be found in APExBIO’s datasheet. For further methodological guidance, internal articles such as "Optimizing Cell Assays with WY-14643 (Pirinixic Acid)" offer practical insights for maximizing reproducibility in metabolic and inflammation studies.